hit counter

14 New ADHD Medications In the Pipeline (2015)

ADHD (attention-deficit/hyperactivity disorder) is a condition characterized by inability to concentrate and often comorbid hyperactive behaviors.  It is considered the most common psychiatric disorder among children and adolescents (affecting approximately 5%) and is fairly common among adults (affecting approximately 4%).  Individuals with ADHD may face serious difficulties completing projects, studying at school, holding a steady …

Read more

20 New Antidepressants In The Pipeline (2015): Drugs In Clinical Trials

For individuals in the United States between the age of 15 and 44, major depression is the leading cause of disability.  Major depression is often a heritable condition, caused by maladaptive genes getting transferred across generations.  That said, not everyone diagnosed with major depressive disorder inherited the condition from ancestors or should be blaming their …

Read more

Rexulti (Brexpiprazole) Approved For Schizophrenia & Depression (Adjunct)

Rexulti (Brexpiprazole) is a drug that was approved July 10, 2015 for the treatment of schizophrenia and as an adjunctive option for major depressive disorder.  In clinical trials it was referred to as the chemical “OPC-34712” and is being marketed as a superior successor to Abilify (Aripiprazole) due to the fact that Abilify’s patent expired …

Read more

Antidepressant Trials May Exclude Over 82% of People with Depression

A recent publication in the Journal of Psychiatric Practice documented that nearly 4/5 individuals diagnosed with major depression are considered ineligible to participate in clinical trials for new antidepressant drugs.  This means that for every 5 individuals with depression that attempt to join an antidepressant clinical trial, only one will meet inclusion criteria for registration.  …

Read more

LY-2456302 For Depression: Kappa Opioid Receptor (KOR) Antagonist

In recent years, biotech and pharmaceutical companies have been developing new classes of antidepressants. These new classes attempt to improve on older classes of medication in regards to efficacy, side effects, and tolerability. One such class that is being developed is that which targets opioid receptors, particularly the kappa receptor. These drugs are classified as …

Read more

NSI-189 For Depression: New Drug Grows Hippocampus

Individuals diagnosed with major depression often are found to have reduced volume within their hippocampus. The hippocampus is a small region of the brain that is responsible for regulating various memory and spatial navigation functions. It is also believed to play a pivotal role in the regulation of mood. Modern day antidepressants such as SSRIs …

Read more